| Heather Louise Straub, MD | |
|
12605 E 16th Ave, Aurora, CO 80045 | |
| (720) 777-1234 | |
| Not Available |
| Full Name | Heather Louise Straub |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 17 Years |
| Location | 12605 E 16th Ave, Aurora, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083902597 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Physicians Incorporated | 3476465667 | 2657 |
News Archive
In this post in the Global Health Governance blog, Jenilee Guebert, director of research for the global health diplomacy program and G8 research group at the University of Toronto's Munk School of Global Affairs, writes that, "for the second year in a row, the amount of attention devoted to global health" at the annual G8 summit, which took place at Camp David in Maryland in May, has declined.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced the Company has completed business negotiations with one of the U.S. Government's top national security research institutions regarding the acquisition of rights to the Integrated Optical Biosensor System (IBOS) technology developed by the laboratory personnel. Biomagnetics Diagnostics plans to utilize this technology to enter the significantly underserved market for handheld biosensors capable of detecting a broad range of disease-causing viruses, bacteria and fungi.
A study published this week by ITG revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year. Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that deterred some physicians from adopting the new drug.
In a study with mice, Johns Hopkins Bloomberg School of Public Health researchers have found that e-cigarettes compromise the immune system in the lungs and generate some of the same potentially dangerous chemicals found in traditional nicotine cigarettes.
› Verified 9 days ago
| Entity Name | University Physicians Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962461889 PECOS PAC ID: 3476465667 Enrollment ID: O20031105000375 |
News Archive
In this post in the Global Health Governance blog, Jenilee Guebert, director of research for the global health diplomacy program and G8 research group at the University of Toronto's Munk School of Global Affairs, writes that, "for the second year in a row, the amount of attention devoted to global health" at the annual G8 summit, which took place at Camp David in Maryland in May, has declined.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced the Company has completed business negotiations with one of the U.S. Government's top national security research institutions regarding the acquisition of rights to the Integrated Optical Biosensor System (IBOS) technology developed by the laboratory personnel. Biomagnetics Diagnostics plans to utilize this technology to enter the significantly underserved market for handheld biosensors capable of detecting a broad range of disease-causing viruses, bacteria and fungi.
A study published this week by ITG revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year. Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that deterred some physicians from adopting the new drug.
In a study with mice, Johns Hopkins Bloomberg School of Public Health researchers have found that e-cigarettes compromise the immune system in the lungs and generate some of the same potentially dangerous chemicals found in traditional nicotine cigarettes.
› Verified 9 days ago
| Entity Name | Catholic Health Initiatives Colorado |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356783351 PECOS PAC ID: 8022927342 Enrollment ID: O20031215000462 |
News Archive
In this post in the Global Health Governance blog, Jenilee Guebert, director of research for the global health diplomacy program and G8 research group at the University of Toronto's Munk School of Global Affairs, writes that, "for the second year in a row, the amount of attention devoted to global health" at the annual G8 summit, which took place at Camp David in Maryland in May, has declined.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced the Company has completed business negotiations with one of the U.S. Government's top national security research institutions regarding the acquisition of rights to the Integrated Optical Biosensor System (IBOS) technology developed by the laboratory personnel. Biomagnetics Diagnostics plans to utilize this technology to enter the significantly underserved market for handheld biosensors capable of detecting a broad range of disease-causing viruses, bacteria and fungi.
A study published this week by ITG revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year. Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that deterred some physicians from adopting the new drug.
In a study with mice, Johns Hopkins Bloomberg School of Public Health researchers have found that e-cigarettes compromise the immune system in the lungs and generate some of the same potentially dangerous chemicals found in traditional nicotine cigarettes.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Heather Louise Straub, MD Po Box 110429, Aurora, CO 80042-0429 Ph: (303) 493-7000 | Heather Louise Straub, MD 12605 E 16th Ave, Aurora, CO 80045 Ph: (720) 777-1234 |
News Archive
In this post in the Global Health Governance blog, Jenilee Guebert, director of research for the global health diplomacy program and G8 research group at the University of Toronto's Munk School of Global Affairs, writes that, "for the second year in a row, the amount of attention devoted to global health" at the annual G8 summit, which took place at Camp David in Maryland in May, has declined.
Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced the Company has completed business negotiations with one of the U.S. Government's top national security research institutions regarding the acquisition of rights to the Integrated Optical Biosensor System (IBOS) technology developed by the laboratory personnel. Biomagnetics Diagnostics plans to utilize this technology to enter the significantly underserved market for handheld biosensors capable of detecting a broad range of disease-causing viruses, bacteria and fungi.
A study published this week by ITG revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year. Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that deterred some physicians from adopting the new drug.
In a study with mice, Johns Hopkins Bloomberg School of Public Health researchers have found that e-cigarettes compromise the immune system in the lungs and generate some of the same potentially dangerous chemicals found in traditional nicotine cigarettes.
› Verified 9 days ago
Catherine Elizabeth Callinan, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1635 Aurora Ct, Aurora, CO 80045 Phone: 720-848-0000 | |
Christianne Persenaire, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1665 Aurora Ct Fl 2, Aurora, CO 80045 Phone: 303-724-2066 Fax: 303-724-2053 | |
Kian Behbakht, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Amanda Jean Johnson, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Ivy L Lersten, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 13001 E 17th Pl, Aurora, CO 80045 Phone: 303-724-2052 Fax: 303-724-2055 | |
Nicholas Behrendt, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 12605 E 16th Ave, Aurora, CO 80045 Phone: 720-848-0000 | |
Sz-min Harley, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1400 S Potomac St, #220, Aurora, CO 80012 Phone: 303-690-2198 Fax: 303-369-1807 |